Penumbra marked a -3.2% change today, compared to -1.0% for the S&P 500. Is it a good value at today's price of $223.73? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally.
-
Penumbra belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
-
The company's P/B ratio is 8.06
-
Penumbra has a trailing 12 month Price to Earnings (P/E) ratio of 310.7 based on its trailing 12 month price to earnings (EPS) of $0.72 per share
-
Its forward P/E ratio is 80.5, based on its forward earnings per share (EPS) of $2.78
-
PEN has a Price to Earnings Growth (PEG) ratio of 0.72, which shows the company is very undervalued compared to its earnings growth estimates.
-
Over the last four years, Penumbra has averaged free cash flows of $16.79 Million, which on average grew -0.0%
-
PEN's gross profit margins have averaged 64.3 % over the last four years and during this time they had a growth rate of 0.0 % and a coefficient of variability of 4.2 %.
-
Penumbra has moved 15.0% over the last year compared to 14.0% for the S&P 500 -- a difference of 1.0%
-
PEN has an average analyst rating of buy and is -32.6% away from its mean target price of $331.92 per share